Biopharma Stocks: Strong In The Good Times, But Even Better During Bad
Executive Summary
As biotech stocks start to look a bit top-heavy and choppy, how well do biotech and pharma function as “defensive” stocks for investors looking to escape the brutalities of a bear market?